Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ12111212-0,08
KB104310451,26
PKN86,1586,180,37
Msft502502,68-0,23
Nokia4,3774,380,92
IBM289290-0,22
Mercedes-Benz Group AG52,4152,420,29
PFE25,5625,570,00
10.07.2025 14:32:01
Indexy online
AD Index online
select
AD Index online
 

  • 09.07.2025
HCW Biologics Rg (NASDAQ Cons)
Závěr k 9.7.2025 Změna (%) Změna (USD) Objem obchodů (ks)
4,32 4,73 0,20 32 444
Premarket10.07.2025 14:24:29
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
4,30 4,30 4,31 -0,35 -0,02 764
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 10.07.2025
Popis společnosti
Obecné informace
Název společnostiHcw Biologics Inc
TickerHCWB
Kmenové akcie:Ordinary Shares
RICHCWB.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 36
Akcie v oběhu k 29.05.2025 1 971 359
MěnaUSD
Kontaktní informace
Ulice2929 N Commerce Pkwy, Miramar, Fl 33025
MěstoMIRAMAR
PSČ33025
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon19 548 422 024
Fax19548422037

Business Summary: HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Hcw Biologics Inc revenues decreased 100% to $5K. Net loss decreased 71% to $2.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Selling/General/Admin Expens decrease of 90% to $454K (expense), Manufacturing and materials decrease of 54% to $263K (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 10.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Founder, DirectorHing Wong71
Chief Financial OfficerRebecca Byam69
Senior Vice President - Business DevelopmentLee Flowers79
Chief Scientific Officer, Vice President - Clinical OperationsPeter Rhode67